April 20, 2016
April 20, 2016 - PRESSADVANTAGE -
ZofranLegal.com has reported that many of the plaintiffs involved in the ongoing Zofran litigation have included results from the Andersen Study in their complaint.
The Andersen Study was performed in 2013. Researchers analyzed over 900,000 birth records from the National Hospital Register in Denmark between the years of 1997 and 2010. They paid particular attention to mothers who had been prescribed the anti-nausea medication Zofran to treat morning sickness or hyperemesis gravidarum during the first trimester. Ultimately, they concluded that mothers who took Zofran were more likely to give birth to a child with a congenital heart defect and that they were 2 to 4 times more likely to have a baby who suffered from a septal cardiac defect. They also determined that there was an increased risk for the development of malformations by 30%.
There are currently more than 230 complaints consolidated in MDL 2657. In each case, parents are alleging that the only reason their child developed a birth defect was that the mother was prescribed Zofran during her pregnancy and the child was exposed to the drug while still in the womb. Cardiac defects, kidney defects, cleft lip and palate, respiratory distress syndrome, and clubfoot are all birth defects that plaintiffs are claiming were caused by the drug.
This isn’t the first time that GlaxoSmithKline, the manufacturer of Zofran, has faced a lawsuit regarding the drug. The U.S. Department of Justice previously filed a lawsuit against the company alleging that they had unlawfully promoted several drugs for “off-label” use, including Zofran. GSK never admitted to any wrongdoing, however, they did end up paying nearly 3 billion dollars in fines in a settlement agreement in 2012.
The litigation is expected to continue growing and the attorneys at Monheit Law are working to ensure that parents who believe their child may have been harmed by the drug have the opportunity to explore their legal options. The firm is offering free consultations to qualified families. Learn more by calling 877-620-8411.
###
For more information about ZofranLegal.com, contact the company here:
ZofranLegal.com
Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046
Sponsored by an alliance of attorneys, ZofranLegal.com is a resource for parents, families and birth defect survivors interested in learning more about litigation surrounding the nausea drug Zofran and its link to increased risks of major birth defects.
Michael Monheit
1368 Barrowdale Road, Rydal, PA 19046
1-877-620-8411
michael@monheit.com
Visit Website
